FIA
ALLO icon

FNY Investment Advisers’s Allogene Therapeutics ALLO Stock Holding History

FNY Investment Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-700
Closed -$17K – 766
2020
Q4 		$17K Buy
700
+400
+133% +$13K ﹤0.01% 541
2020
Q3 		$11K Buy
+300
New +$11.3K ﹤0.01% 327

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FNY Investment Advisers's ALLO Position: Q1 2021 in Review

FNY Investment Advisers sold out of Allogene Therapeutics (ALLO) in Q1 2021, closing a stake of 700 shares — an estimated $17K sold.

FNY Investment Advisers first reported a position in ALLO in Q3 2020 and held it in 2 quarters. The position peaked at $17K in Q4 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q1 2021.

  • FNY Investment Advisers reported no remaining Allogene Therapeutics position as of Q1 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 700 Allogene Therapeutics shares in Q1 2021, an estimated $17K.
  • FNY Investment Advisers first reported a position in Allogene Therapeutics in Q3 2020 and held it in 2 quarters.
  • FNY Investment Advisers's Allogene Therapeutics position peaked at $17K in Q4 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2021.

Based on FNY Investment Advisers's 13F filing for Q1 2021, filed 12 Apr 2021.